False Positives, Overdiagnosis, and Incidental Findings

What this means

Three different problems get sold as “we found something early.” A false positive is a test that looks abnormal when the target disease is absent. Overdiagnosis is a real lesion or cancer that would never have caused symptoms or death if nobody had looked. An incidental finding is an unexpected abnormality unrelated to the reason for testing—an “incidentaloma” on a scan ordered for wellness or for another organ.

NCI’s patient screening overview lists false-positive results, false-negative results, and the fact that finding a cancer may not help a person live longer. Its professional overview adds overdiagnosis and the complications of follow-up procedures. Those are not rare footnotes. They are why USPSTF and ACS write age, risk, and interval limits instead of “scan everyone.”

Positive predictive value depends on how common the disease is. A reasonably accurate test used in a very low-risk group can still produce more false alarms than true cases. Large panels and whole-body images multiply chance abnormalities. FDA consumer pages on whole-body CT screening warn that these exams can find things that start more tests, including findings that were never going to harm you.

A cascade of repeat labs, contrast, biopsy, or surgery can be necessary. It can also be net harm. You cannot judge a test by how many abnormalities it prints.

What the evidence shows

Guideline screening accepts some false positives because trials showed fewer deaths from specific cancers in defined groups. NCI notes that mammography and PSA testing can have false-positive rates in the range of about 5 to 10 percent per screen, and that the cumulative rate rises with repeat testing. Follow-up biopsy is usually safe and still not free: infection, bleeding, and anxiety are real.

Overdiagnosis is hardest to see in an individual. NCI’s explainer on screening statistics describes lead-time bias and length bias. Finding a slow-growing lesion earlier can make five-year survival look better without changing the date of death. Estimates of overdiagnosis are substantial for some screen-detected breast and prostate cancers. That is why shared decision-making exists for PSA and why not every image-detected lesion is treated at once.

Incidental findings are the expected output of untargeted imaging. A whole-body MRI in a well adult will often show cysts, disc degeneration, or small nodules. Some need a protocol. Many need a letter that says “likely benign, repeat once, then stop.” Without that plan, people bounce between cash scans. Radiation from CT, contrast reactions, and procedure complications accumulate even when the original finding was harmless.

Low-value testing also creates false negatives and false reassurance. A normal executive MRI does not clear the colon. A multi-cancer blood test with a negative signal does not replace USPSTF-aligned mammography or colonoscopy. NCI frames mortality benefit—not detection counts—as the question that justifies a screen.

• False positive: extra tests for a disease that is not there.
• Overdiagnosis: real disease that treatment cannot improve because it would never have mattered.
• Incidental finding: an off-target abnormality that still needs a named owner.

Common myths

Myth: “More sensitive is always better.” Raising sensitivity without a workup plan increases alarms. NCI’s professional pages treat false positives and overdiagnosis as design problems, not proof that the clinic is thorough.

Myth: “If they found it, it would have killed me.” That is the overdiagnosis error. Some lesions are indolent. Treating every one as an emergency is how screening harms people who would have stayed well.

Myth: “A full-body scan is just a better annual physical.” FDA material on whole-body CT says these exams are not established screening for asymptomatic people and involve radiation. MRI avoids ionizing radiation and still generates incidentalomas. Neither replaces blood pressure, smoking cessation, or indicated cancer screening.

Myth: “A negative boutique test means I can skip colonoscopy.” False negatives exist. So do cancers the test was never designed to find. ACS and USPSTF recommendations stay in place after a wellness package.

Myth: “Anxiety is not a medical harm.” NCI lists anxiety and invasive follow-up as reasons a screen can hurt. Months of waiting for a repeat nodule check is a cost, even when the nodule is later called benign.

How clinics use it

Careful clinics use these words before the draw or the scan. They name the target disease, the expected false-positive rate in people like you, and the next test if the result is abnormal. They distinguish a screening test from a diagnostic test for a symptom. They have a radiologist or physician who will manage incidental findings instead of a dashboard email.

Sales-driven rooms do the opposite. They treat every extra marker as personalization. They show a gallery of “cancers we caught” without a denominator or a mortality endpoint. They upsell a repeat whole-body exam instead of sending you back to indicated stool testing or mammography. They call an incidental cyst a reason to join a membership.

Some clinics use incidental findings ethically: they document the lesion, apply a guideline interval, and stop imaging when stability is shown. That is ordinary radiology. The red flag is a clinic that both creates the incidentaloma and sells the indefinite follow-up as longevity care.

Ask who interprets the image, whether the lab is CLIA-certified, and whether a positive result has a covered confirmatory path. A test without an owner for the cascade is not prevention. It is risk transfer to you.

Practical takeaway

Start with pretest probability, not the menu. If you are due for a USPSTF A or B cancer screen, do that test. If you have a new symptom, get a diagnostic visit. If you are well and low-risk, a broader net is more likely to produce alarms than saved lives.

1. Name the disease the test is meant to find and the decision a result would change.
2. Ask for false-positive, overdiagnosis, and incidental-finding rates in people like you—not a celebrity anecdote.
3. Write down the follow-up for positive, negative, and uncertain results before you pay.
4. Keep indicated screening even after a reassuring boutique package.

After an unexpected result, confirm the specimen or image, compare priors, and use specialty guidance. Do not start a supplement stack because a wellness report used the word “nodule.” Do not ignore a finding that a clinician says needs a biopsy. The skill is matching the response to the problem type: wrong alarm, harmless true finding, or a lesion that actually changes care.

Set a stop rule. One optional scan or panel is enough unless a research protocol explains the next sample. Count procedures and worry as outcomes, not only detections. Licensed clinicians—not a detection scoreboard—decide when a finding is worth treating.